Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Withdrawn Not applicable Interventional

Augmented Reality Heads-up Display to Improve Ultrasound Guided IV Access

NCT05710445
View directory record Official record
Conditions
Phlebotomy
Interventions
Augmented Reality
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 31, 2026, 1:23 AM EDT
Terminated Phase 3 Interventional

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

NCT03699956
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
Combination Product · Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Denver, Colorado • Orange City, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 31, 2026, 1:23 AM EDT
Terminated Phase 3 Interventional

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

NCT01875653
View directory record Official record
Conditions
Stage IV Melanoma, Stage III Melanoma
Interventions
Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC)
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 31, 2026, 1:23 AM EDT
Withdrawn Phase 3 Interventional

Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women

NCT03854396
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Postmenopause, Postmenopausal Syndrome, Postmenopausal Symptoms, Menopause
Interventions
Prasterone, Placebo
Drug
Lead sponsor
Olivia Cardenas-Trowers, M.D.
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 31, 2026, 1:23 AM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

NCT04912856
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

NCT00003141
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
66
States / cities
Duarte, California • Los Angeles, California • Madera, California + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 31, 2026, 1:23 AM EDT
Terminated Phase 1 Interventional

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

NCT00238173
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)

NCT01669746
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured mixed population of dermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
7
States / cities
Tucson, Arizona • Santa Rosa, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

NCT05506969
View directory record Official record
Conditions
Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
Interventions
rF1V-1018, rF1V vaccine
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss

NCT03057873
View directory record Official record
Conditions
Overweight
Interventions
High protein, high fiber dietary supplement, Placebo
Dietary Supplement
Lead sponsor
Beachbody
Industry
Eligibility
25 Years to 50 Years
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 31, 2026, 1:23 AM EDT
Recruiting Phase 4 Interventional

Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks

NCT06574022
View directory record Official record
Conditions
Mastectomy; Lymphedema, Breast Cancer
Interventions
Bupivacain, Exparel, Intraoperative Pecs II block (IOB) & superior AT (EX or BP), Preoperative Pecs II block (POB) & superior AT (EX or BP)
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 2 Interventional

Campath-1H + FK506 and Methylprednisolone for GVHD

NCT00109993
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, tacrolimus
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
New York, New York • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 31, 2026, 1:23 AM EDT
Withdrawn Not applicable Interventional

A Novel Unconditional Gifted Savings Program

NCT06119074
View directory record Official record
Conditions
Poverty
Interventions
Gifted Savings
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 31, 2026, 1:23 AM EDT
Active, not recruiting Phase 2 Interventional

Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

NCT04323735
View directory record Official record
Conditions
Neurogenic Bladder
Interventions
Culturelle 10 Billion CFU Capsule
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT03030248
View directory record Official record
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen

NCT01710449
View directory record Official record
Conditions
COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Diseases
Interventions
perfluorinated gas/oxygen mixture
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 31, 2026, 1:23 AM EDT
Recruiting Phase 3 Interventional

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

NCT04411225
View directory record Official record
Conditions
Early Psychosis
Interventions
Cannabidiol oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
16 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 31, 2026, 1:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Arterial Stiffness in Type I Diabetes Mellitus

NCT02218268
View directory record Official record
Conditions
Arterial Stiffness in Youth With Type 1 Diabetes
Interventions
Pre-meal bolus, No meal bolus
Drug
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 31, 2026, 1:23 AM EDT
Terminated Not applicable Interventional

Use of a Medical Food in Adults Undergoing Surgery

NCT04041908
View directory record Official record
Conditions
Compliance, Patient
Interventions
Experimental Product
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 3 Interventional

An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents

NCT00067262
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium Extended-Release Tablets
Drug
Lead sponsor
Abbott
Industry
Eligibility
10 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
16
States / cities
Stanford, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 3 Interventional

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

NCT06462586
View directory record Official record
Conditions
Bipolar Disorder, Manic
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
23
States / cities
Rogers, Arkansas • Bellflower, California • Culver City, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 1:23 AM EDT
Withdrawn Phase 4 Interventional

Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

NCT00572689
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Exenatide, Buccal/blood Sample Collection
Drug · Genetic
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 31, 2026, 1:23 AM EDT
Not yet recruiting Phase 2 Interventional

A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization

NCT07792915
View directory record Official record
Conditions
Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
Interventions
Resistant Potato Starch, Maltodextrin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 1:23 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Lymphoma

NCT00002835
View directory record Official record
Conditions
Lymphoma
Interventions
Bleomycin Sulfate (BLM), Filgrastim (G-CSF), Recombinant Interferon Alfa, Carmustine, Cisplatin (CDDP), Cyclophosphamide, Cytarabine (ARA-C), Etoposide (VP-16), Idarubicin, Ifosfamide, Leucovorin Calcium, Melphalan, Methotrexate, Methylprednisolone, mitoxantrone hydrochloride (DHAD), Vincristine Sulfate, Peripheral Blood Stem Cell Transplantation, Radiation Therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 59 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 31, 2026, 1:23 AM EDT